Cargando…
Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System
Hepatocellular carcinoma (HCC) is a highly malignant tumor related to high mortality and is still lacking a satisfactory cure. Tumor metastasis is currently a major challenge of cancer treatment, which is highly related to angiogenesis. The vascular endothelial growth factor (VEGF)/VEGFR signaling p...
Autores principales: | Li, Xunan, Wang, Xiang, Liu, Nian, Wang, Qiuyu, Hu, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000533/ https://www.ncbi.nlm.nih.gov/pubmed/35408480 http://dx.doi.org/10.3390/molecules27072082 |
Ejemplares similares
-
Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011) -
Expression of alpha-GalNAc glycoproteins by breast cancers.
por: Brooks, S. A., et al.
Publicado: (1995) -
The GalNAc-T Activation (GALA) Pathway: Drivers and markers
por: Chia, Joanne, et al.
Publicado: (2019) -
The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
por: Pacheco-Sánchez, Marisol, et al.
Publicado: (2023) -
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)